Assessment of patients with Covid-19 hospitalized in southern Santa Catarina

Schuelter-Trevisol, Fabiana; Raimundo, Leonan José; Soccas, Hadymilla Duarte; Antunes, Ariana Francisco; Mohr, Regina Longen Degering; Marcon, Chaiana Esmeraldino Mendes; Trevisol, Daisson José

doi:10.1590/0037-8682-0579-2020

Acessibilidade / Reportar erro

Brasil

Revista da Sociedade Brasileira de Medicina Tropical

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

Short Communication • Rev. Soc. Bras. Med. Trop. 53 • 2020 • https://doi.org/10.1590/0037-8682-0579-2020 copy

Assessment of patients with Covid-19 hospitalized in southern Santa Catarina

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstract

INTRODUCTION:

Coronavirus disease 2019 (COVID-19), a potentially fatal disease, is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The number of cases has increased rapidly, but information on the clinical characteristics remains limited.

METHODS:

Cohort study. We collected and analyzed epidemiological, demographic, and clinical data of critically and noncritically ill patients and compared the outcomes.

RESULTS:

The mean age of hospitalized patients with COVID-19 was 54 years (standard deviation 16.9; 53.8% men), 29% required ICU admission, and 18.6% died.

CONCLUSIONS:

The main risk factors for ICU admission were age over 60 years, obesity, and preexisting chronic lung diseases.

Keywords:
Coronavirus infections; Hospitalization; Severe acute respiratory syndrome

Characteristics	n	%
Gender
Male	113	53.6
Female	98	46.4
Age
0-9	1	0.5
10-19	-	-
20-29	12	5.7
30-39	33	15.6
40-49	48	22.7
50-59	37	17.5
60-69	40	19.0
70-79	25	11.8
80-89	11	5.2
90-99	4	1.9
Comorbidities
Arterial hypertension	67	31.9
Diabetes mellitus	37	17.6
Chronic heart diseases	27	12.9
Obesity	18	8.6
Neurologic/psychiatric diseases	17	8.1
Chronic lung diseases	15	7.1
Dyslipidemia	8	3.8
Smoking habits	6	2.9
Cancer	6	2.9
Chronic kidney diseases	5	2.4
Vascular diseases	3	1.4
ICU
Yes	61	29.0
No	150	71.1
Pharmacological treatment
Azithromycin	162	76.8
Hydroxychloroquine	15	7.1
Dexamethasone	102	48.3
Anticoagulants	188	89.1
Other corticosteroids	110	52.1
Disclosure
Discharged	155	73.5
Death	41	19.4
Transfer to another hospital	4	1.9
Hospitalization	11	5.2
	Median	Min - Max
Time of hospitalization in days
Infirmary	4	1-36
ICU	13	0-115

	ICU				Death
	OR crude	P-value	OR adjusted	P-value	OR crude	P-value	OR adjusted	P-value
	(CI 95%)		(CI 95%)		(CI 95%)		(CI 95%)
Age ≥ 60 years old	3.14 (1.69-5.82)	<0.001	3.59 (1.67-7.69)	0.001	11.06 (4.70-26.00)	<0.001	10.67 (4.05-28.10)	<0.001
Male gender	1.50 (0.82-2.75)	0.188	-		1.48 (0.72-3.04)	0.281	-
Comorbidities	3.29 (1.73-6.28)	<0.001	0.97 (0.35-2.69)	0.958	3.88 (1.73-8.71)	0.001	2.82 (0.90-8.90)	0.076
Arterial hypertension	2.65 (1.42-4.94)	0.002	1.10 (0.44-2.76)	0.840	2.62 (1.28-5.39)	0.009	0.59 (0.20-1.74)	0.341
Diabetes mellitus	1.63 (0.78-3.43)	0.197	-		2.09 (0.92-4.74)	0.077	-
Chronic heart disease	2.61 (1.15-5.95)	0.022	2.09 (0.74-5.92)	0.165	2.86 (1.15-7.14)	0.024	0.98 (0.31-3.10)	0.974
Obesity	3.46 (1.29-9.24)	0.013	6.83 (1.93-24.25)	0.003	1.79 (0.59-5.42)	0.303	-
Neurologic/psychiatric diseases	3.05 (1.12-8.33)	0.029	2.65 (0.78-8.96)	0.118	1.97 (0.64-6.03)	0.238	-
Chronic lung diseases	4.13 (1.40-12.16)	0.010	4.04 (1.20-16.13)	0.025	3.01 (1.00-9.04)	0.050	2.54 (0.63-10.17)	0.188
Dyslipidemia	4.35 (1.01-18.79)	0.049	2.64 (0.48-14.68)	0.266	0.81 (0.09-7.10)	0.845	-
Smoking habits	5.16 (0.92-28.94)	0.062	-		2.79 (0.45-17.32)	0.270	-
Cancer	0.48 (0.06-4.20)	0.507	-		2.08 (0.37-11.80)	0.408	-
Chronic kidney diseases	3.80 (0.62-23.34)	0.149	-		17.93 (1.95-165.49)	0.011	4.11 (0.40-42.00)	0.233
Vascular diseases	5.02 (0.45-56.38)	0.191	-		-	-	-

Sociedade Brasileira de Medicina Tropical - SBMT Caixa Postal 118, 38001-970 Uberaba MG Brazil, Tel.: +55 34 3318-5255 / +55 34 3318-5636/ +55 34 3318-5287, http://rsbmt.org.br/ - Uberaba - MG - Brazil
E-mail: rsbmt@uftm.edu.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] Corresponding author: Dr. Fabiana Schuelter Trevisol e-mail:fastrevisol@gmail.com